Henry F. Chambers

41.8k total citations · 10 hit papers
257 papers, 27.6k citations indexed

About

Henry F. Chambers is a scholar working on Infectious Diseases, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, Henry F. Chambers has authored 257 papers receiving a total of 27.6k indexed citations (citations by other indexed papers that have themselves been cited), including 187 papers in Infectious Diseases, 100 papers in Epidemiology and 92 papers in Clinical Biochemistry. Recurrent topics in Henry F. Chambers's work include Antimicrobial Resistance in Staphylococcus (170 papers), Bacterial Identification and Susceptibility Testing (92 papers) and Antibiotic Resistance in Bacteria (55 papers). Henry F. Chambers is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (170 papers), Bacterial Identification and Susceptibility Testing (92 papers) and Antibiotic Resistance in Bacteria (55 papers). Henry F. Chambers collaborates with scholars based in United States, United Kingdom and Canada. Henry F. Chambers's co-authors include Frank R. DeLeo, Sheldon L. Kaplan, Catherine Liu, Arnold S. Bayer, C J Hackbarth, Michaël Otto, James C. Wade, Sherwood L. Gorbach, José G. Montoya and Jan V. Hirschmann and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Henry F. Chambers

246 papers receiving 26.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

2011 3.1k citations Arnold S. Bayer, Sara E. Cosgrove et al. Clinical Infectious Diseases profile →
Waves of resistance: Staphylococcus aureus in the antibiotic era

2009 2.0k citations Henry F. Chambers, Frank R. DeLeo profile →
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America

2014 1.7k citations Henry F. Chambers et al. Clinical Infectious Diseases profile →
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary

2011 1.2k citations Arnold S. Bayer, Sara E. Cosgrove et al. Clinical Infectious Diseases profile →
Community-associated meticillin-resistant Staphylococcus aureus

2010 1.2k citations Frank R. DeLeo, Michaël Otto et al. profile →
The Changing Epidemiology of Staphylococcus aureus?

2001 1.1k citations Henry F. Chambers profile →
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections

2005 1.1k citations Henry F. Chambers et al. Clinical Infectious Diseases profile →
Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America

2014 1.0k citations Henry F. Chambers et al. Clinical Infectious Diseases profile →
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications

1997 838 citations Henry F. Chambers profile →
Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children

2022 80 citations Melinda M. Pettigrew, Vance G. Fowler et al. profile →

Peers

Countries citing papers authored by Henry F. Chambers

Since Specialization

Citations

This map shows the geographic impact of Henry F. Chambers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry F. Chambers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry F. Chambers more than expected).

Fields of papers citing papers by Henry F. Chambers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry F. Chambers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry F. Chambers. The network helps show where Henry F. Chambers may publish in the future.

Co-authorship network of co-authors of Henry F. Chambers

This figure shows the co-authorship network connecting the top 25 collaborators of Henry F. Chambers. A scholar is included among the top collaborators of Henry F. Chambers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry F. Chambers. Henry F. Chambers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interagency Collaboration for Patient-Centered Antibacterial Drug Development 2025 ·Clinical Infectious Diseases ·Jessica Howard‐Anderson, Sarah B. Doernberg, Dennis O. Dixon, Ramya Gopinath, Daniel B. Rubin, (unknown), Peter Kim, Deborah Collyar, Sara E. Cosgrove, Vance G. Fowler, Henry F. Chambers, Scott Evans, Thomas L Holland, (unknown), Helen W. Boucher	0
2	Intertwining clonality and resistance: Staphylococcus aureus in the antibiotic era 2024 ·Journal of Clinical Investigation ·Henry F. Chambers, Vance G. Fowler	7
3	Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021 2024 ·Clinical Infectious Diseases ·(unknown), (unknown), Jessica Galloway-Peña, David van Duin, Leila Ledbetter, Keri Baum, Felicia Ruffin, Jane M. Knisely, (unknown), Vance G. Fowler, Henry F. Chambers, Melinda M. Pettigrew	2
4	The Positioning of Ceftobiprole in the Treatment of Staphylococcus aureus Bacteremia 2024 ·Clinical Infectious Diseases ·Daniel J. Minter, Ayesha Appa, Henry F. Chambers, Sarah B. Doernberg	0
5	A molecular analysis of meropenem–vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae 2024 ·Antimicrobial Agents and Chemotherapy ·Mohamad Yasmin, Steven H. Marshall, Liang Chen, Daniel D. Rhoads, Michael R. Jacobs, Laura J. Rojas, Federico Pérez, Andrea M. Hujer, Kristine M. Hujer, David van Duin, Vance G. Fowler, Henry F. Chambers, Barry N. Kreiswirth, Robert A. Bonomo, (unknown)	0
6	In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals 2024 ·Antimicrobial Agents and Chemotherapy ·Alina Iovleva, Christi L. McElheny, (unknown), Eric Cober, Erica Herc, César A. Arias, Carol Hill, Keri Baum, Vance G. Fowler, Henry F. Chambers, Kerryl E. Greenwood‐Quaintance, Robin Patel, David van Duin, Robert A. Bonomo, Yohei Doi	15
7	Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs 2024 ·Clinical Infectious Diseases ·(unknown), (unknown), (unknown), Daniel B. Rubin, Deborah Collyar, Sarah B. Doernberg, Scott Evans, Toshimitsu Hamasaki, Thomas L Holland, Jessica Howard‐Anderson, Henry F. Chambers, Vance G. Fowler, (unknown), Peter Kim, Helen W. Boucher, Ramya Gopinath	0
8	Contemporary Management of Staphylococcus aureus Bacteremia—Controversies in Clinical Practice 2023 ·Clinical Infectious Diseases ·Daniel J. Minter, Ayesha Appa, Henry F. Chambers, Sarah B. Doernberg	17
9	Role of the NaHCO ₃ Transporter MpsABC in the NaHCO ₃ –β-Lactam-Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus 2023 ·Microbiology Spectrum ·(unknown), Richard A. Proctor, Selvi C. Ersoy, Adhar C. Manna, Ambrose L. Cheung, Friedrich Götz, Henry F. Chambers, Arnold S. Bayer	2
10	Structural basis of broad-spectrum β-lactam resistance in Staphylococcus aureus 2023 ·Nature ·J. Andrew N. Alexander, L.J. Worrall, Jinhong Hu, M. Vuckovic, (unknown), Raymond Poon, Solmaz Sobhanifar, Federico I. Rosell, Joshua Jenkins, (unknown), (unknown), Henry F. Chambers, Mark Paetzel, Som S. Chatterjee, N.C.J. Strynadka	35
11	Executive Summary: State-of-The-Art Review: Contemporary Management of Staphylococcus aureus Bacteremia: Controversies in Clinical Practice 2023 ·Clinical Infectious Diseases ·Daniel J. Minter, Ayesha Appa, Henry F. Chambers, Sarah B. Doernberg	4
12	Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics 2019 ·Antimicrobial Agents and Chemotherapy ·Selvi C. Ersoy, Wessam Abdelhady, Liang Li, Henry F. Chambers, Yan Q. Xiong, Arnold S. Bayer	28
13	Ability of Bicarbonate Supplementation To Sensitize Selected Methicillin-Resistant Staphylococcus aureus Strains to β-Lactam Antibiotics in an Ex Vivo Simulated Endocardial Vegetation Model 2019 ·Antimicrobial Agents and Chemotherapy ·Warren E. Rose, (unknown), Yan Q. Xiong, Henry F. Chambers, Arnold S. Bayer, Selvi C. Ersoy	19
14	Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults 2018 ·Clinical Infectious Diseases ·Thomas L Holland, Henry F. Chambers, Helen W. Boucher, G. Ralph Corey, Rebecca Coleman, (unknown), Vance G. Fowler	30
15	Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus 2009 ·Proceedings of the National Academy of Sciences ·Min Li, Binh An Diep, Amer E. Villaruz, Kevin R. Braughton, Xiaofei Jiang, Frank R. DeLeo, Henry F. Chambers, Yuan Lu, Michaël Otto	322
16	In Vitro Selection and Characterization of Ceftobiprole-Resistant Methicillin-Resistant Staphylococcus aureus 2008 ·Antimicrobial Agents and Chemotherapy ·Ritu Banerjee, Michael Gretes, Li Basuino, N.C.J. Strynadka, Henry F. Chambers	74
17	Mechanism of cell surface expression of the Streptococcus mitis platelet binding proteins PblA and PblB 2007 ·Molecular Microbiology ·Jennifer Mitchell, Ian R. Siboo, Daisuke Takamatsu, Henry F. Chambers, Paul M. Sullam	61
18	Randomized, Double-Blind, Placebo-Controlled Trial of Cephalexin for Treatment of Uncomplicated Skin Abscesses in a Population at Risk for Community-Acquired Methicillin-Resistant Staphylococcus aureus Infection 2007 ·Antimicrobial Agents and Chemotherapy ·Priya Rajendran, David M. Young, Toby Maurer, Henry F. Chambers, Françoise Perdreau‐Remington, (unknown), Hobart W. Harris	158
19	The Changing Epidemiology of Staphylococcus aureus? 2001 ·SHILAP Revista de lepidopterología ·Henry F. Chambers	121
20	Treatment of Infection and Colonization Caused by Methicillin-Resistant Staphylococcus aureus 1991 ·Infection Control and Hospital Epidemiology ·Henry F. Chambers	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact